Showing 1 to 9 of 9
| Title | Consultation | Type | Consultation end date | Sort date |
|---|---|---|---|---|
| Faltering growth | Quality standard consultation | Quality standard | Type:21 February 2020 | 20200221 |
| Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400] | Appraisal consultation | Technology appraisal guidance | Type:21 February 2020 | 20200221 |
| Preterm labour and birth | Surveillance consultation | NICE guideline | Type:26 February 2020 | 20200226 |
| Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426] | Appraisal consultation | Technology appraisal guidance | Type:04 March 2020 | 20200304 |
| Electrical stimulation to improve muscle strength in non-neurological chronic conditions | Interventional procedure consultation | Interventional procedures guidance | Type:05 March 2020 | 20200305 |
| Behaviour change: digital and mobile health interventions | Draft guidance consultation | NICE guideline | Type:06 March 2020 | 20200306 |
| Suspected neurological conditions | Quality standard consultation | Quality standard | Type:11 March 2020 | 20200311 |
| Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder | Draft guidance: 1 | Medical technologies guidance | Type:13 March 2020 | 20200313 |
| Acute coronary syndromes | Draft guidance consultation | NICE guideline | Type:27 March 2020 | 20200327 |